Skip to main content

ASCO 2021 - Breast Cancer

Moderate physical activity reduced the inflammatory response triggered by neoadjuvant chemotherapy in breast cancer patients prior to surgery. The benefit appears to be lost after surgery. Read More ›

Diverse factors contribute to shifts in psychosocial function in breast cancer patients after treatment. Understanding these factors provides opportunities for patients to receive more holistic care. Read More ›

Actionable biomarkers associated with directed treatment to prevent or reverse symptoms in African Americans with advanced-stage breast cancer may reduce mortality rates. Read More ›

The SOLAR-1 and X2101 trials demonstrate long-term disease control can be attained for ≥18 months with alpelisib plus fulvestrant in patients with hard-to-treat HR-positive/HER2-negative advanced breast cancer. Read More ›

Many women with HR-positive breast cancer contend with emotional distress during prolonged adjuvant endocrine therapy. Behavioral interventions show promise as effective strategies to reduce stress and improve adherence to therapy. Read More ›

Telehealth visits provide increased access to care for oncology patients across multiple demographics with reported high patient satisfaction with level of care. Read More ›

Low socioeconomic status is associated with delayed access to age-appropriate cancer screenings due to cost of care. Read More ›

Perceived fatigability may be a more clinically relevant measurement of the effectiveness of exercise intervention on reducing fatigue among survivors of breast cancer. Read More ›

Advanced-stage diagnosis of breast cancer is associated with deprived-rural socioeconomic status in French women. Read More ›

Alpelisib may overcome resistance to CDK4/6 inhibitors in HR-positive/HER2-negative advanced breast cancer patients with shorter exposure to prior CDK4/6 inhibitor treatment. Read More ›

Page 1 of 2